Related Experiment Video

Updated: Mar 1, 2026

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

9.9K

Serotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus

Emily J Simon1, Morgan A Howells2, Johnasha D Stuart3

  • 1Department of Microbiology and Immunology and Center for Microbial Pathogenesis and Host Inflammatory Response, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. esimon@uams.edu.

Viruses
|June 8, 2017
PubMed

Insights

Reovirus shows promise as a cancer therapeutic. Recombinant reovirus type 1 (rsT1L) demonstrated superior cancer cell killing compared to type 3 (rsT3D) in specific non-small cell lung cancer types.

Area of Science:

  • Oncolytic virology
  • Cancer therapeutics
  • Molecular virology

Background:

  • Reovirus is being developed as an oncolytic virus therapy for various cancers.
  • Genetic manipulation has not yet improved reovirus safety or efficacy.
  • Understanding strain-specific differences is crucial for optimizing reovirus oncolytics.

Purpose of the Study:

  • To evaluate the oncolytic potential of recombinant reovirus strains T1L and T3D.
  • To compare the efficacy of rsT1L and rsT3D against non-small cell lung cancer (NSCLC) cell lines.
  • To identify viral determinants responsible for strain-specific differences in cytolysis.

Main Methods:

  • Testing recombinant strains rsT1L and rsT3D on NSCLC cell lines.
  • Comparing cell death kinetics and magnitude induced by recombinant and non-recombinant strains.
  • Identifying specific reovirus gene segments (L2, L3, M1) influencing cytolytic differences.

Main Results:

  • rsT1L exhibited greater cytolytic activity than rsT3D in large cell carcinoma lines.
  • Both strains showed comparable efficacy against adenocarcinoma cell lines.
  • Non-recombinant T1L and T3D strains mirrored the cell death patterns of their recombinant counterparts.
  • Viral gene segments L2, L3, and M1 were identified as key determinants of strain-specific killing.

Conclusions:

  • Recombinant reoviruses accurately reflect the oncolytic properties of their non-recombinant predecessors.
  • Type 1 reoviruses may offer superior oncolytic potential compared to type 3 in certain cancer types.
  • These findings establish a foundation for engineering enhanced reovirus-based cancer therapies.
Keywords:
lung canceroncolysisreovirusreverse genetics

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.5K

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.7K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.1K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.2K
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.0K